Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Hair loss discussion includes fluridil (eucapil) and alfatradiol. Users share improvement experiences and alternative treatments in comments.

The conversation is about someone considering using Minoxidil combined with a weak antiandrogen for hair loss, but is concerned about potential increased hair loss if they stop using Minoxidil. They are seeking others' experiences with stopping Minoxidil and the effects on their hair.

A 19-year-old female with Diffuse Alopecia was advised by a dermatologist to use vitamin supplements, a hair serum, and antifungal drops, leading to some improvement. Other users suggested treatments like minoxidil, microneedling, and consulting a different dermatologist for further advice.

The user suspects scarring alopecia and is exploring NSAIDs and turmeric/pepper for inflammation-related hair loss, having experienced burning and thinning with finasteride and testosterone reduction. They are seeking feedback while unable to afford a dermatologist.

The conversation is about using liposomal finasteride for hair loss treatment, highlighting its cost-effectiveness and ease of preparation. It suggests using lecithin and crushed finasteride pills to make the solution, which has shown to be significantly more effective than other topical formulations.

The conversation is about someone considering using CB-03-01 for hair loss but has ordered finasteride, which they are hesitant to use. They are seeking advice on how to prepare CB-03-01 from powder form and the appropriate strength to use.

User is experiencing issues with Minoxidil and is considering switching to Redensyl, specifically asking for brand recommendations. The Ordinary - Multi Peptide is mentioned, but the user seeks other brand experiences.

A 30-year-old man with diffuse hair thinning shared his hair regrowth regimen, which includes increasing Vitamin D intake, taking oral castor oil, using a dermapen, and various supplements like Glycine, K2, Vitamin E, Vitamin C, Aspirin, Sodium Bicarbonate, and a multivitamin. He also mentioned inconsistent use of Minoxidil, Peppermint Oil, Zix, and topical Castor Oil, and negative side effects from Finasteride, RU58841, and Nizoral.

A user shared early positive results after 51 days using finasteride, minoxidil, a DHT blocking shampoo, biotin gummies, and dermarolling to treat hair loss. They noticed new vellus hairs and improved hair density, and provided photos as evidence.

The conversation discusses how applying topical tretinoin for 5 days can convert 43% of individuals who initially do not respond to minoxidil into responders, enhancing the effect of minoxidil on hair growth. Specific treatments mentioned are minoxidil and tretinoin.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

Chronic Telogen Effluvium can be managed by avoiding inflammatory foods, exercising, staying hydrated, and using supplements like krill oil, saw palmetto, or licorice root. Minoxidil is discouraged due to its cost and potential for worsening hair loss, while castor oil is recommended to strengthen hair roots and reduce shedding.

Hydrocortisone helps relieve scalp itchiness, possibly caused by minoxidil. Users discuss its effectiveness for managing this side effect.

The conversation discusses using Cedarwood, Rosemary, and Lavender essential oils for hair growth and preventing hair loss. The user plans to apply Cedarwood oil daily.

A user is experiencing mild hair loss and is hesitant to try finasteride due to potential side effects. They are considering using Research Verified Hair Growth, which contains various vitamins and minerals, and are seeking opinions and experiences from others.

Nizoral shampoo reduced shedding but caused hair dryness. Alternatives like non-SLS ketoconazole shampoos, such as Regenpure DR, are recommended for use 2-3 times a week to avoid dryness.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

The user is using 0.5mg dutasteride and 2.5mg minoxidil for hair loss and is considering additional treatments like microneedling and RU58841. They feel discouraged due to lack of progress on the crown/mid scalp but are advised to be patient and consistent, as improvements can take up to a year.

The conversation discusses whether a 2 in 1 shampoo and conditioner with ketoconazole 1% is less effective than using the shampoo alone for someone with a dry scalp and seborrheic dermatitis. The focus is on choosing the right product for hair and scalp health.

Finasteride reduces DHT production, so blood tests can track hormonal changes. Pyrilutamide blocks androgen receptors without altering hormone levels, making blood tests less useful for detecting its effects.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.